Apreensões de medicamentos genéricos em portos europeus e a agenda anticontrafação: implicações para o acesso a medicamentos

Faria, Janaína Elisa Patti.
Rio de Janeiro; ABIA; 2011. 45 p. tab.
Monografia em Português | Coleciona SUS (Brasil) | ID: biblio-935517

Documentos relacionados

  1. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
  2. A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs.
  3. Protecting the rights of producers original medicines.
  4. Ontario regulations prohibiting the listing of private label drug products upheld.
  5. Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling".
  6. A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme.
  7. Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint.
  8. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
  9. [Shortage of supply of drugs in Spain. A health problem].
  10. EU implicated in controversial counterfeiting bill.